Cargando…

Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients

BACKGROUND: Gluconeogenesis and renal glucose excretion in kidneys both play an important role in glucose homeostasis. Sodium-glucose cotransporter (SGLT2), coded by the SLC5A2 gene is responsible for reabsorption up to 99% of the filtered glucose in proximal tubules. SLC5A2 genetic polymorphisms we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klen, Jasna, Goričar, Katja, Dolžan, Vita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Medical Biochemists of Serbia, Belgrade 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682783/ https://www.ncbi.nlm.nih.gov/pubmed/33269015 http://dx.doi.org/10.2478/jomb-2019-0040

Ejemplares similares

The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment
por: Klen, Jasna, et al.
Publicado: (2014)

NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients
por: Klen, Jasna, et al.
Publicado: (2015)

SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
por: Klen, Jasna, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
por: Klen, Jasna, et al.
Publicado: (2022)

Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations
por: Klen, Jasna, et al.
Publicado: (2021)

The Influence of Genetic Variability of DNA Repair Mechanisms on the Risk of Malignant Mesothelioma
por: Levpuscek, Kristina, et al.
Publicado: (2019)

Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review
por: Vogrinc, David, et al.
Publicado: (2021)

The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2018)

Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome
por: Herman, Rok, et al.
Publicado: (2020)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
por: Herat, Lakshini Y., et al.
Publicado: (2018)

Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients
por: Marinko, Tanja, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy
por: Wakisaka, Masarori, et al.
Publicado: (2017)

Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
por: Cho, Eun Hyung, et al.
Publicado: (2018)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

The Influence of Genetic Variability in IL1B and MIR146A on the Risk of Pleural Plaques and Malignant Mesothelioma
por: Piber, Petra, et al.
Publicado: (2020)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal
por: Gupta, Vishal, et al.
Publicado: (2017)

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
por: Chiba, Koki, et al.
Publicado: (2020)

Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage
por: Goricar, Katja, et al.
Publicado: (2012)

Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia
por: Gammons, D. Taylor, et al.
Publicado: (2018)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
por: Wang, Yaowen, et al.
Publicado: (2016)

Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
por: Goricar, Katja, et al.
Publicado: (2020)

Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes
por: Lu, Jingyi, et al.
Publicado: (2018)

The Role of Glycemic Control and Variability in Diabetic Retinopathy
por: Chatziralli, Irini P.
Publicado: (2017)

Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study
por: Tsermpini, Evangelia Eirini, et al.
Publicado: (2022)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz, Stanley S, et al.
Publicado: (2016)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis
por: Jingfan, Zhang, et al.
Publicado: (2019)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh, Hala, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema
por: Takatsuna, Yoko, et al.
Publicado: (2020)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
por: Xiang, Boyang, et al.
Publicado: (2021)

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease
por: Wakisaka, Masanori, et al.
Publicado: (2021)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
por: Takata, Tomoaki, et al.
Publicado: (2021)

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
por: Tahrani, Abd A., et al.
Publicado: (2011)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
por: Kim, Yoojin, et al.
Publicado: (2012)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
por: John, Mathew, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ql09is8th8s5m1nvmtts58kggr